Hemodialysis Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)
発行: Mordor Intelligence Pvt Ltd
ページ情報: 英文 125 Pages
The Hemodialysis Market is projected to register a CAGR of 5.6% during the forecast period.
The COVID-19 pandemic has been continuing to transform the growth of various markets, the immediate impact of the outbreak is varied. While a few industries registered a drop in demand, numerous other markets may continue to remain unscathed and show promising growth opportunities. Initially, the outbreak of COVID-19 worldwide and the lockdown situation across some countries have shown some challenges on the market studied, due to hold on services by the hospitals and clinics, in order to prevent the spread of the COVID-19 virus. In addition, people with existing illnesses, such as acute kidney injury (AKI) and chronic kidney disease (CKD), hypertension, and diabetes, are expected to experience a higher-than-average fatality rate. For instance, as per the report published by National Kidney Foundation Inc., in 2020, stated that people hospitalized with COVID-19 are at significant risk of CKD, which can lead to serious illness like end stage renal disease. Thus, rising incidence of kidney failure and chronic renal dysfunction due to COVID-19 is expected to promote the market growth over the forecast period.
Moreover, the major factors for the growth of the hemodialysis market include the rising number of end-stage renal disease (ESRD) patients and the increasing incidence of diabetes and hypertension.
The rise in the number of ESRD and shortage in the availability of kidneys for transplant is expected to boost the growth of the market. Chronic kidney disease (CKD) is a condition that causes reduced kidney function over a period of time. It may develop over many years and lead to end-stage kidney (or renal) disease (ESRD). It has become an enormous public health issue that continues to rise. For instance, as per a 2019 report by the Center for Disease Control and Prevention, 15% of the adults in the United States, which accounts for approximately 37 million people, is estimated to have CKD. In addition, as per the same source CKD is common among people aged 65 years or older (38%) than in people aged 45-64 years (13%) or 18-44 years (7%). Furthermore, it is more common in women (15%) than men (12%).
Furthermore, High blood pressure (hypertension) and diabetes are the principal causes of kidney disease and kidney failure. In the patients with diabetes, the small blood vessels in the body are injured and may cause damage to nerves resulting in improper blood purification by the kidneys and emptying bladder further leading to kidney failure. As per the World Health Organization, in 2019, an estimated 1.13 billion people worldwide had hypertension, with most patients (two-thirds) living in low- and middle-income countries. Moreover, hypertension is one of the major causes of premature death worldwide. In addition, As per the International Diabetes Federation (IDF) Diabetes Atlas Ninth edition 2019, it was found that globally approximately 463 million adults (20-79 years) were living with diabetes, and by 2045, it is expected to reach 700 million. Thus, owing to the rising burden of kidney failures there will be a huge demand for hemodialysis equipment resulting in high growth of the market.
Conventional Long-Term Hemodialysis is the Segment by Modality is Expected to Hold Largest Market Share over the Forecast Period
The COVID-19 pandemic has affected hemodialysis procedures. However, in order to cope up with the crisis created by COVID 19, In July 2020 NephroPlus has launched India's first "Dialysis on Wheels" Program where a patient can undergo dialysis inside an ambulance itself that comes to their home. In addition, the relaxation in lockdown guidelines are also increasing the therapeutic procedural rate which further increases the segment growth.
The hemodialysis market is segmented by Modality in three major segments Conventional Long-Term Hemodialysis, Short Daily Hemodialysis, and Nocturnal hemodialysis. Conventional Long-Term Hemodialysis is expected to hold a large market share owing to the huge acceptance of hemodialysis therapy over peritoneal dialysis among CKD and ESRD patients.
According to the Organ Procurement and Transplantation Network around 90,986 people as of February 2021 are waiting for kidney transplants in the United States. Thus, owing to the shortage of kidneys for transplant the market is expected to witness high growth.
Furthermore, major manufacturers have been focusing on developing specialized dialysis equipment coupled with growing partnerships and collaboration among market players, which is expected to drive the market's growth. Currently, various home and in-center hemodialysis machines are available in the market.
In October 2020, Fresenius Medical Care North America (FMCNA), entered into an innovative partnership with Livongo Health, Inc, to improve the lives and outcomes of people with late-stage chronic kidney disease (CKD) by increasing optimal dialysis starts, as well as offer earlier evaluation of transplantation and home dialysis options. In additon In 2019, CVS Health initiated a Clinical trial for its new HemoCare Hemodialysis System, a dialysis machine developed for home use in partnership with Segway designer Dean Kamen.
North America is Expected to Hold Largest Market Share over the Forecast Period
The United States is the most COVID-affected country across the world. Initially, due to the lockdown, a delay in diagnosis and treatments is being observed in many of the patients, including end-stage renal disease patients, as a result of a reduction in hospital visits. Hence this factor had affected the hemodialysis market growth in the COVID-19 pandemic.
Moreover, As COVID-19 has a high mortality rate among older adults and individuals suffering from chronic diseases, such as chronic kidney diseases (CKD). As per the Centers for Disease Control and Prevention (CDC) 2019, in the United States, about 15% of adults suffer from chronic kidney diseases (CKD). In addition in the United States, patients with pre-existing chronic kidney disease (CKD) were considered to be largely susceptible to COVID-19. For instance, a research article by Jennifer E Flythe et al, published in the American Journal of Kidney Diseases 2020, stated that high mortality can be observed in patients with underlying kidney disease and severe COVID-19.
Moreover, the United States is expected to be the largest market for hemodialysis owing to the presence of better healthcare infrastructure and the presence of major market players. As per the Center for disease control and prevention 2018, 15% of US adults or 37 million people are estimated to have chronic kidney disease common in people aged 65 years or older (38%) than in people aged 45-64 years (13%) or 18-44 years.
In addition, As per the Chronic Kidney Disease in the United States, 2019 report, the number of people living with CKD in the United States had been found to be 37 million, and CKD is more common in women (15%) than men (12%). Moreover, according to the same report, CKD is known as one of the costliest disease conditions in the United States, which has been posing an economic burden of USD 83 billion annually. In addition, according to the Population Reference Bureau, the number of Americans ages 65 and older is projected to nearly double from 52 million in 2018 to 95 million by 2060. An aging population and growing risk of chronic kidney disease projected to significantly boost regional growth.
Furthermore, the manufacturers are focusing on developing specialized hemodialysis, machines with different interventions. This is expected to impact the end-user experience. In addition, there is also an increase in public healthcare expenditure, coupled with the rising awareness programs, which is expected to drive the growth of the hemodialysis market in North America region.
The market studied is a moderately consolidated market owing to the presence of few market players. Some of the market players are Asahi Kasei Corporation, B. Braun Melsungen AG, Baxter International Inc., Becton, Dickinson and Company, Cantel Medical Corp., DaVita Inc., Fresenius Medical Care AG & Co. KGaA, Medtronic PLC, and Nipro Corporation